(NVO) Novo Nordisk - Ratings and Ratios
Exchange: NYSE •
Country: Denmark •
Currency: USD •
Type: Common Stock •
ISIN: US6701002056
Insulin, Obesity, Growth, Blood, Hormone
Dividends
| Dividend Yield | 3.35% |
| Yield on Cost 5y | 5.34% |
| Yield CAGR 5y | 2.54% |
| Payout Consistency | 90.2% |
| Payout Ratio | 7.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 37.7% |
| Value at Risk 5%th | 55.4% |
| Relative Tail Risk | -10.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.31 |
| Alpha | -64.83 |
| CAGR/Max DD | -0.11 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.420 |
| Beta | 0.764 |
| Beta Downside | 0.802 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.50% |
| Mean DD | 22.03% |
| Median DD | 8.16% |
Description: NVO Novo Nordisk December 01, 2025
Novo Nordisk A/S (NYSE:NVO) is a Danish-based, globally active pharmaceutical group that develops, manufactures, and markets drugs across two main segments: Diabetes & Obesity Care and Rare Disease. The Diabetes & Obesity segment covers insulin, GLP-1 agonists, and emerging cardiovascular therapies, while the Rare Disease segment focuses on treatments for rare blood and endocrine disorders, plus hormone replacement products. The company also supplies delivery devices such as insulin and growth-hormone pens, and offers digital tools like smart insulin pens and the Dose Check app to improve adherence.
Key metrics that reinforce Novo Nordisk’s market position include 2023 revenue of ≈ DKK 140 billion (~US$ 20 bn) and an R&D spend of ≈ DKK 13 billion, representing roughly 9 % of sales-well above the pharmaceutical industry average. The firm’s GLP-1 portfolio (e.g., Ozempic, Wegovy) has driven double-digit growth, capitalising on the global rise in obesity prevalence (projected to affect > 1 billion adults by 2030). Additionally, Novo Nordisk’s partnership with Valo Health aims to accelerate cardiometabolic drug discovery, reflecting a broader industry shift toward AI-enabled pipeline development.
For a deeper quantitative view, you may find ValueRay’s analyst dashboard useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (103.77b TTM) > 0 and > 6% of Revenue (6% = 18.94b TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA -6.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -16.63% (prev -4.88%; Δ -11.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 123.78b > Net Income 103.77b (YES >=105%, WARN >=100%) |
| Net Debt (69.13b) to EBITDA (163.70b) ratio: 0.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.45b) change vs 12m ago -0.31% (target <= -2.0% for YES) |
| Gross Margin 82.05% (prev 84.66%; Δ -2.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.38% (prev 68.08%; Δ 1.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.15 (EBITDA TTM 163.70b / Interest Expense TTM 17.96b) >= 6 (WARN >= 3) |
Altman Z'' 3.08
| (A) -0.10 = (Total Current Assets 181.88b - Total Current Liabilities 234.36b) / Total Assets 512.29b |
| (B) 0.33 = Retained Earnings (Balance) 168.53b / Total Assets 512.29b |
| (C) 0.32 = EBIT TTM 146.44b / Avg Total Assets 454.86b |
| (D) 0.50 = Book Value of Equity 169.90b / Total Liabilities 342.39b |
| Total Rating: 3.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.51
| 1. Piotroski 6.0pt |
| 2. FCF Yield 4.40% |
| 3. FCF Margin 19.88% |
| 4. Debt/Equity 0.60 |
| 5. Debt/Ebitda 0.42 |
| 6. ROIC - WACC (= 35.88)% |
| 7. RoE 66.95% |
| 8. Rev. Trend 96.64% |
| 9. EPS Trend 87.97% |
What is the price of NVO shares?
As of December 14, 2025, the stock is trading at USD 50.18 with a total of 11,633,366 shares traded.
Over the past week, the price has changed by +4.85%, over one month by -0.16%, over three months by -8.55% and over the past year by -52.52%.
Over the past week, the price has changed by +4.85%, over one month by -0.16%, over three months by -8.55% and over the past year by -52.52%.
Is NVO a buy, sell or hold?
Novo Nordisk has received a consensus analysts rating of 3.50.
Therefor, it is recommend to hold NVO.
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the NVO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 53.3 | 6.1% |
| Analysts Target Price | 53.3 | 6.1% |
| ValueRay Target Price | 42.1 | -16% |
NVO Fundamental Data Overview December 06, 2025
Market Cap DKK = 1356.50b (213.24b USD * 6.3613 USD.DKK)
P/E Trailing = 13.2204
P/E Forward = 12.1212
P/S = 0.6757
P/B = 8.0361
P/EG = 1.6197
Beta = 0.352
Revenue TTM = 315.60b DKK
EBIT TTM = 146.44b DKK
EBITDA TTM = 163.70b DKK
Long Term Debt = 89.18b DKK (from longTermDebt, last quarter)
Short Term Debt = 12.03b DKK (from shortTermDebt, last quarter)
Debt = 101.21b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.13b DKK (from netDebt column, last quarter)
Enterprise Value = 1425.13b DKK (1356.50b + Debt 101.21b - CCE 32.58b)
Interest Coverage Ratio = 8.15 (Ebit TTM 146.44b / Interest Expense TTM 17.96b)
FCF Yield = 4.40% (FCF TTM 62.74b / Enterprise Value 1425.13b)
FCF Margin = 19.88% (FCF TTM 62.74b / Revenue TTM 315.60b)
Net Margin = 32.88% (Net Income TTM 103.77b / Revenue TTM 315.60b)
Gross Margin = 82.05% ((Revenue TTM 315.60b - Cost of Revenue TTM 56.66b) / Revenue TTM)
Gross Margin QoQ = 76.12% (prev 83.29%)
Tobins Q-Ratio = 2.78 (Enterprise Value 1425.13b / Total Assets 512.29b)
Interest Expense / Debt = 4.95% (Interest Expense 5.01b / Debt 101.21b)
Taxrate = 21.60% (5.51b / 25.52b)
NOPAT = 114.81b (EBIT 146.44b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 181.88b / Total Current Liabilities 234.36b)
Debt / Equity = 0.60 (Debt 101.21b / totalStockholderEquity, last quarter 169.90b)
Debt / EBITDA = 0.42 (Net Debt 69.13b / EBITDA 163.70b)
Debt / FCF = 1.10 (Net Debt 69.13b / FCF TTM 62.74b)
Total Stockholder Equity = 155.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.26% (Net Income 103.77b / Total Assets 512.29b)
RoE = 66.95% (Net Income TTM 103.77b / Total Stockholder Equity 155.00b)
RoCE = 59.97% (EBIT 146.44b / Capital Employed (Equity 155.00b + L.T.Debt 89.18b))
RoIC = 44.36% (NOPAT 114.81b / Invested Capital 258.80b)
WACC = 8.49% (E(1356.50b)/V(1457.71b) * Re(8.83%) + D(101.21b)/V(1457.71b) * Rd(4.95%) * (1-Tc(0.22)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 76.79% ; FCFE base≈67.37b ; Y1≈73.42b ; Y5≈92.50b
Fair Price DCF = 413.8 (DCF Value 1393.93b / Shares Outstanding 3.37b; 5y FCF grow 10.21% → 3.0% )
EPS Correlation: 87.97 | EPS CAGR: 96.11% | SUE: 1.50 | # QB: 1
Revenue Correlation: 96.64 | Revenue CAGR: 19.59% | SUE: -0.03 | # QB: 0
EPS next Year (2026-12-31): EPS=21.94 | Chg30d=-2.437 | Revisions Net=-4 | Growth EPS=-4.1% | Growth Revenue=-0.1%
P/E Trailing = 13.2204
P/E Forward = 12.1212
P/S = 0.6757
P/B = 8.0361
P/EG = 1.6197
Beta = 0.352
Revenue TTM = 315.60b DKK
EBIT TTM = 146.44b DKK
EBITDA TTM = 163.70b DKK
Long Term Debt = 89.18b DKK (from longTermDebt, last quarter)
Short Term Debt = 12.03b DKK (from shortTermDebt, last quarter)
Debt = 101.21b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.13b DKK (from netDebt column, last quarter)
Enterprise Value = 1425.13b DKK (1356.50b + Debt 101.21b - CCE 32.58b)
Interest Coverage Ratio = 8.15 (Ebit TTM 146.44b / Interest Expense TTM 17.96b)
FCF Yield = 4.40% (FCF TTM 62.74b / Enterprise Value 1425.13b)
FCF Margin = 19.88% (FCF TTM 62.74b / Revenue TTM 315.60b)
Net Margin = 32.88% (Net Income TTM 103.77b / Revenue TTM 315.60b)
Gross Margin = 82.05% ((Revenue TTM 315.60b - Cost of Revenue TTM 56.66b) / Revenue TTM)
Gross Margin QoQ = 76.12% (prev 83.29%)
Tobins Q-Ratio = 2.78 (Enterprise Value 1425.13b / Total Assets 512.29b)
Interest Expense / Debt = 4.95% (Interest Expense 5.01b / Debt 101.21b)
Taxrate = 21.60% (5.51b / 25.52b)
NOPAT = 114.81b (EBIT 146.44b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 181.88b / Total Current Liabilities 234.36b)
Debt / Equity = 0.60 (Debt 101.21b / totalStockholderEquity, last quarter 169.90b)
Debt / EBITDA = 0.42 (Net Debt 69.13b / EBITDA 163.70b)
Debt / FCF = 1.10 (Net Debt 69.13b / FCF TTM 62.74b)
Total Stockholder Equity = 155.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.26% (Net Income 103.77b / Total Assets 512.29b)
RoE = 66.95% (Net Income TTM 103.77b / Total Stockholder Equity 155.00b)
RoCE = 59.97% (EBIT 146.44b / Capital Employed (Equity 155.00b + L.T.Debt 89.18b))
RoIC = 44.36% (NOPAT 114.81b / Invested Capital 258.80b)
WACC = 8.49% (E(1356.50b)/V(1457.71b) * Re(8.83%) + D(101.21b)/V(1457.71b) * Rd(4.95%) * (1-Tc(0.22)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 76.79% ; FCFE base≈67.37b ; Y1≈73.42b ; Y5≈92.50b
Fair Price DCF = 413.8 (DCF Value 1393.93b / Shares Outstanding 3.37b; 5y FCF grow 10.21% → 3.0% )
EPS Correlation: 87.97 | EPS CAGR: 96.11% | SUE: 1.50 | # QB: 1
Revenue Correlation: 96.64 | Revenue CAGR: 19.59% | SUE: -0.03 | # QB: 0
EPS next Year (2026-12-31): EPS=21.94 | Chg30d=-2.437 | Revisions Net=-4 | Growth EPS=-4.1% | Growth Revenue=-0.1%
Additional Sources for NVO Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle